http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6638974-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_59c6a921f33fe0adc58c2b6177184515 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-34 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-34 |
| filingDate | 2000-04-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2003-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3edf898bacdaafcfefd8511ad7fc16f9 |
| publicationDate | 2003-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-6638974-B1 |
| titleOfInvention | Ascorbyl esters for the treatment of cancer |
| abstract | There is provided a method of treating cancer by treating the cancer cells with a lipophilic derivative of ascorbic acid. Also provided is a method of inhibiting the Ras pathway by administering a lipophilic derivative of ascorbic acid. A method of inducing apoptosis in cancer cells is also provided by treating cancer cells with a lipophilic derivative of ascorbic acid. A pharmaceutical composition for the treatment of cancer comprising a lipophilic derivative of ascorbic acid in a pharmaceutically acceptable carrier is also provided. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016069458-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2023181603-A1 |
| priorityDate | 1999-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 90.